Patents by Inventor John T. POIRIER

John T. POIRIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOLIGAND BINDING TO ANTI-DLL3 ANTIBODIES FOR PRETARGETED PET IMAGING AND THERAPEUTIC USES THEREOF
    Publication number: 20240216557
    Abstract: The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.
    Type: Application
    Filed: February 28, 2024
    Publication date: July 4, 2024
    Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Tri-Institutional Therapeutics Discovery Institute, Inc.
    Inventors: John T. POIRIER, Charles Rudin, Jason Lewis, Abdul Khan, David Andrew, Xinlei Chen, Ivo C. Lorenz, Kathryn M. Tully, Salomon Tendler
  • ANTI-DLL3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20240115721
    Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
    Publication number: 20240115720
    Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 11, 2024
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
  • DLL3-TARGETING ANTIBODIES AND USES THEREOF
    Publication number: 20220348648
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.
    Type: Application
    Filed: July 8, 2020
    Publication date: November 3, 2022
    Inventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ